| 摘要 |
An agent for treatment of metabolic bone disease, which contains EPO as an active ingredient, or a method for treating a patient with metabolic bone disease, which comprises EPO, is provided. Pharmaceutical products containing EPO as the active ingredient are novel prophylactic and therapeutic agents which show an ameliorative action by healing bone and bone marrow lesions in bone disease, especially bone disease based on impaired bone metabolism, aside from the previously reported erythrocyte increasing action of EPO. Pathological states, targeted by these pharmaceutical products, are bone diseases showing metabolic bone disorders, including renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, and osteoporosis.
|
